Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

NCT05749276 · clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
12
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Nantes University Hospital